Lexicon Secures $1 Billion Deal with Novo Nordisk for Obesity Candidate
Lexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read more